370 related articles for article (PubMed ID: 30275402)
1. Inflammation and the Gut-Liver Axis in the Pathophysiology of Cholangiopathies.
Giordano DM; Pinto C; Maroni L; Benedetti A; Marzioni M
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30275402
[TBL] [Abstract][Full Text] [Related]
2. Role of the Gut-Liver Axis in the Pathobiology of Cholangiopathies: Basic and Clinical Evidence.
Bragazzi MC; Venere R; Vignone A; Alvaro D; Cardinale V
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047635
[TBL] [Abstract][Full Text] [Related]
3. Role of inflammation and proinflammatory cytokines in cholangiocyte pathophysiology.
Pinto C; Giordano DM; Maroni L; Marzioni M
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1270-1278. PubMed ID: 28754451
[TBL] [Abstract][Full Text] [Related]
4. Cholangiocyte pathobiology.
Banales JM; Huebert RC; Karlsen T; Strazzabosco M; LaRusso NF; Gores GJ
Nat Rev Gastroenterol Hepatol; 2019 May; 16(5):269-281. PubMed ID: 30850822
[TBL] [Abstract][Full Text] [Related]
5. Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies-A Critical Overview.
Kasztelan-Szczerbinska B; Rycyk-Bojarzynska A; Szczerbinska A; Cichoz-Lach H
Nutrients; 2023 Feb; 15(3):. PubMed ID: 36771465
[TBL] [Abstract][Full Text] [Related]
6. Gut-Liver Axis and Inflammasome Activation in Cholangiocyte Pathophysiology.
Maroni L; Ninfole E; Pinto C; Benedetti A; Marzioni M
Cells; 2020 Mar; 9(3):. PubMed ID: 32192118
[TBL] [Abstract][Full Text] [Related]
7. Biliary innate immunity in the pathogenesis of biliary diseases.
Harada K; Nakanuma Y
Inflamm Allergy Drug Targets; 2010 Jun; 9(2):83-90. PubMed ID: 20402650
[TBL] [Abstract][Full Text] [Related]
8. Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma.
Chung BK; Karlsen TH; Folseraas T
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1390-1400. PubMed ID: 28844951
[TBL] [Abstract][Full Text] [Related]
9. The Cholangiopathies.
Lazaridis KN; LaRusso NF
Mayo Clin Proc; 2015 Jun; 90(6):791-800. PubMed ID: 25957621
[TBL] [Abstract][Full Text] [Related]
10. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
[TBL] [Abstract][Full Text] [Related]
11. The gut-liver axis in cholangiopathies: focus on bile acid based pharmacological treatment.
Cariello M; Gadaleta RM; Moschetta A
Curr Opin Gastroenterol; 2022 Mar; 38(2):136-143. PubMed ID: 35034082
[TBL] [Abstract][Full Text] [Related]
12. Cellular senescence in the cholangiopathies: a driver of immunopathology and a novel therapeutic target.
Trussoni CE; O'Hara SP; LaRusso NF
Semin Immunopathol; 2022 Jul; 44(4):527-544. PubMed ID: 35178659
[TBL] [Abstract][Full Text] [Related]
13. Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.
Fabris L; Fiorotto R; Spirli C; Cadamuro M; Mariotti V; Perugorria MJ; Banales JM; Strazzabosco M
Nat Rev Gastroenterol Hepatol; 2019 Aug; 16(8):497-511. PubMed ID: 31165788
[TBL] [Abstract][Full Text] [Related]
14. The dynamic biliary epithelia: molecules, pathways, and disease.
O'Hara SP; Tabibian JH; Splinter PL; LaRusso NF
J Hepatol; 2013 Mar; 58(3):575-82. PubMed ID: 23085249
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiology of cholangiopathies.
Strazzabosco M; Fabris L; Spirli C
J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S90-S102. PubMed ID: 15758666
[TBL] [Abstract][Full Text] [Related]
16. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis.
Liao L; Schneider KM; Galvez EJC; Frissen M; Marschall HU; Su H; Hatting M; Wahlström A; Haybaeck J; Puchas P; Mohs A; Peng J; Bergheim I; Nier A; Hennings J; Reißing J; Zimmermann HW; Longerich T; Strowig T; Liedtke C; Cubero FJ; Trautwein C
Gut; 2019 Aug; 68(8):1477-1492. PubMed ID: 30872395
[TBL] [Abstract][Full Text] [Related]
17. Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis.
Pollheimer MJ; Racedo S; Mikels-Vigdal A; Marshall D; Bowlus C; Lackner C; Madl T; Karlsen TH; Hov JR; Lyman SK; Adamkewicz J; Smith V; Moreau E; Zollner G; Eide TJ; Stojakovic T; Scharnagl H; Gruber HJ; Stauber RE; Trauner M; Fickert P
J Hepatol; 2018 Aug; 69(2):368-377. PubMed ID: 29709678
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs and extracellular vesicles in cholangiopathies.
Olaizola P; Lee-Law PY; Arbelaiz A; Lapitz A; Perugorria MJ; Bujanda L; Banales JM
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1293-1307. PubMed ID: 28711597
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium.
Strazzabosco M; Fiorotto R; Cadamuro M; Spirli C; Mariotti V; Kaffe E; Scirpo R; Fabris L
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1374-1379. PubMed ID: 28754453
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiome in primary sclerosing cholangitis: A review.
Little R; Wine E; Kamath BM; Griffiths AM; Ricciuto A
World J Gastroenterol; 2020 Jun; 26(21):2768-2780. PubMed ID: 32550753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
